82 FR 46251 - Findings of Research Misconduct

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Federal Register Volume 82, Issue 191 (October 4, 2017)

Page Range		46251-46252
FR Document		2017-21367

Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Azza El-Remessy, Ph.D., University of Georgia, College of Pharmacy: Based on the report of an investigation conducted by the University of Georgia, College of Pharmacy (UGCP) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Azza El-Remessy, former Associate Professor, Department of Clinical and Administrative Pharmacy, UGCP, engaged in research misconduct in research supported by National Eye Institute (NEI), National Institutes of Health (NIH), grants R01 EY011766, R01 EY022408, and R01 EY04618, National Heart, Lung, and Blood Institute (NHLBI), NIH, grant R01 HL056259, and National Cancer Institute (NCI), NIH, grant K01 CA89689. ORI found that false Western blot data were included in: <bullet> J Cell Sci. 118(Pt. 1):243-52, 2005 (hereafter referred to as ``J Cell Sci. 2005''). Retraction in: J Cell Sci. 129(16):3203, 2016. <bullet> FASEB J. 21(10):2528-39, 2007 (hereafter referred to as ``FASEB J. 2007''). Retraction in: FASEB J. 31(1):421, 2017. <bullet> PLoS One 8(8):e71868, 2013 (hereafter referred to as ``PLoS One 2013''). As a result of its investigation, UGCP recommended that PLoS One 2013 be corrected. As a result of the investigation, J Cell Sci. 2005 and FASEB J. 2007 have been retracted. ORI found that Respondent intentionally, knowingly, or recklessly used the same Western blot bands to represent different experimental results. Specifically, Respondent reused and relabeled bands in: 1. Figure 3B, J Cell Sci. 2005, to represent p38 bands from retinal cultured endothelial cells in high glucose in the absence of exogenous VEGF and also cells in peroxynitrite in the presence of exogenous VEGF. 2. Figure 4A, J Cell Sci. 2005, to represent nitrotyrosine immunoprecipitations from retinal endothelial cells cultured in normal glucose in the presence or absence of FeTTP; the Respondent also duplicated controls for p85 immunoprecipitation by using three bands representing 2 normal glucose and 1 high glucose treatments, flipping them horizontally (mirror images) to also represent 2 high glucose and 1 peroxynitrite treatments. 3. Figure 4B, J Cell Sci. 2005, to represent p85 immunoprecipitations from retinal endothelial cells stimulated with VEGF and also cells treated with either high glucose or peroxynitrite. 4. Figure 4A, PLoS One 2013, to represent immunoprecipitations for phosphorylated GSK-3 (p-GSK-3) in cells with normal glucose or high glucose for day 1 and to also represent cells treated with VEGF or VEGF+VEGFI (inhibitor); the Respondent also duplicated GSK-3 controls by using the same bands to represent high glucose treatment for day 1 and day 3 treatments, flipping them horizontally, to also represent for VEGF and VEGFRI treatments. 5. Figure 3, FASEB J. 2007, to represent phosphorylated VEGF2 (P- VEGF2) protein expression in microvascular endothelial cells in: Lanes 1 and 8, lanes 2 and 5, and lanes 6 and 7, where each lane represents different experimental conditions. Dr. El-Remessy entered into a Voluntary Settlement Agreement (Agreement) to resolve this matter without further expenditure of time or other resources. Dr. El-Remessy accepts ORI's findings of research misconduct as set forth above but neither admits nor denies ORI's findings of research misconduct. The settlement is not an admission of liability on the part of the Respondent. Dr. El-Remessy voluntarily agreed, beginning on September 12, 2017: (1) To have her research supervised for a period of three (3) years beginning with the effective date of the Agreement; Respondent agreed that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent's duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that she shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) that for three (3) years beginning with the effective date of the Agreement, any institution employing her shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; (3) to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning with the effective date of the Agreement; and (4) that as a condition of the Agreement, Respondent will request that PLoS One 8(8):e71868, 2013 be corrected or retracted.

Federal Register, Volume 82 Issue 191 (Wednesday, October 4, 2017)

[Federal Register Volume 82, Number 191 (Wednesday, October 4, 2017)]
[Notices]
[Pages 46251-46252]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-21367]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Azza El-Remessy, Ph.D., University of Georgia, College of Pharmacy: 
Based on the report of an investigation conducted by the University of 
Georgia, College of Pharmacy (UGCP) and additional analysis conducted 
by ORI in its oversight review, ORI found that Dr. Azza El-Remessy, 
former Associate Professor, Department of Clinical and Administrative 
Pharmacy, UGCP, engaged in research misconduct in research supported by 
National Eye Institute (NEI), National Institutes of Health (NIH), 
grants R01 EY011766, R01 EY022408, and R01 EY04618, National Heart, 
Lung, and Blood Institute (NHLBI), NIH, grant R01 HL056259, and 
National Cancer Institute (NCI), NIH, grant K01 CA89689.
    ORI found that false Western blot data were included in:
     J Cell Sci. 118(Pt. 1):243-52, 2005 (hereafter referred to 
as ``J Cell Sci. 2005''). Retraction in: J Cell Sci. 129(16):3203, 
2016.
     FASEB J. 21(10):2528-39, 2007 (hereafter referred to as 
``FASEB J. 2007''). Retraction in: FASEB J. 31(1):421, 2017.
     PLoS One 8(8):e71868, 2013 (hereafter referred to as 
``PLoS One 2013'').
    As a result of its investigation, UGCP recommended that PLoS One 
2013 be corrected. As a result of the investigation, J Cell Sci. 2005 
and FASEB J. 2007 have been retracted.
    ORI found that Respondent intentionally, knowingly, or recklessly 
used the same Western blot bands to represent different experimental 
results. Specifically, Respondent reused and relabeled bands in:
    1. Figure 3B, J Cell Sci. 2005, to represent p38 bands from retinal 
cultured endothelial cells in high glucose in the absence of exogenous 
VEGF and also cells in peroxynitrite in the presence of exogenous VEGF.
    2. Figure 4A, J Cell Sci. 2005, to represent nitrotyrosine 
immunoprecipitations from retinal endothelial cells cultured in normal 
glucose in the presence or absence of FeTTP; the Respondent also 
duplicated controls for p85 immunoprecipitation by using three bands 
representing 2 normal glucose and 1 high glucose treatments, flipping 
them horizontally (mirror images) to also represent 2 high glucose and 
1 peroxynitrite treatments.
    3. Figure 4B, J Cell Sci. 2005, to represent p85 
immunoprecipitations from retinal endothelial cells stimulated with 
VEGF and also cells treated with either high glucose or peroxynitrite.
    4. Figure 4A, PLoS One 2013, to represent immunoprecipitations for 
phosphorylated GSK-3 (p-GSK-3) in cells with normal glucose or high 
glucose for day 1 and to also represent cells treated with VEGF or 
VEGF+VEGFI (inhibitor); the Respondent also duplicated GSK-3 controls 
by using the same bands to represent high glucose treatment for day 1 
and day 3 treatments, flipping them horizontally, to also represent for 
VEGF and VEGFRI treatments.
    5. Figure 3, FASEB J. 2007, to represent phosphorylated VEGF2 (P-
VEGF2) protein expression in microvascular endothelial cells in: Lanes 
1 and 8, lanes 2 and 5, and lanes 6 and 7, where each lane represents 
different experimental conditions.
    Dr. El-Remessy entered into a Voluntary Settlement Agreement 
(Agreement) to resolve this matter without further expenditure of time 
or other resources. Dr. El-Remessy accepts ORI's findings of research 
misconduct as set forth above but neither admits nor denies ORI's 
findings of research misconduct. The settlement is not an admission of 
liability on the part of the Respondent. Dr. El-Remessy voluntarily 
agreed, beginning on September 12, 2017:
    (1) To have her research supervised for a period of three (3) years 
beginning with the effective date of the Agreement; Respondent agreed 
that prior to the submission of an application for U.S. Public Health 
Service (PHS) support for a research project on which the Respondent's 
participation is proposed and prior to Respondent's participation in 
any capacity on PHS-supported research, Respondent shall ensure that a 
plan for supervision of Respondent's duties is submitted to ORI for 
approval; the supervision plan must be designed to ensure the 
scientific integrity of Respondent's research contribution; Respondent 
agreed that she shall not participate in any PHS-supported research 
until such a supervision plan is submitted to and approved by ORI; 
Respondent agreed to maintain responsibility for compliance with the 
agreed upon supervision plan;
    (2) that for three (3) years beginning with the effective date of 
the Agreement,

[[Page 46252]]

any institution employing her shall submit, in conjunction with each 
application for PHS funds, or report, manuscript, or abstract involving 
PHS-supported research in which Respondent is involved, a certification 
to ORI that the data provided by Respondent are based on actual 
experiments or are otherwise legitimately derived and that the data, 
procedures, and methodology are accurately reported in the application, 
report, manuscript, or abstract;
    (3) to exclude herself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant for a period of three (3) years, beginning with the 
effective date of the Agreement; and
    (4) that as a condition of the Agreement, Respondent will request 
that PLoS One 8(8):e71868, 2013 be corrected or retracted.

FOR FURTHER INFORMATION CONTACT: Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017-21367 Filed 10-3-17; 8:45 am]
BILLING CODE 4150-31-P

Federal Register / Vol. 82, No. 191 / Wednesday, October 4, 2017 / Notices 46251

Administration, 10903 New Hampshire DEPARTMENT OF HEALTH AND controls for p85 immunoprecipitation
Ave., Bldg. 66, Rm. 5441, Silver Spring, HUMAN SERVICES by using three bands representing 2
MD 20993–0002, 301–796–8398; or FDA normal glucose and 1 high glucose
Advisory Committee Information Line, Office of the Secretary treatments, flipping them horizontally
1–800–741–8138 (301–443–0572 in the (mirror images) to also represent 2 high
Findings of Research Misconduct glucose and 1 peroxynitrite treatments.
Washington, DC area), code PEAC.
Please call the Information Line for up- AGENCY: Office of the Secretary, HHS. 3. Figure 4B, J Cell Sci. 2005, to
to-date information on this meeting. represent p85 immunoprecipitations
ACTION: Notice. from retinal endothelial cells stimulated
SUPPLEMENTARY INFORMATION: In the SUMMARY: Notice is hereby given that with VEGF and also cells treated with
Federal Register of July 26, 2017 (82 FR the Office of Research Integrity (ORI) either high glucose or peroxynitrite.
34681), FDA announced that a meeting 4. Figure 4A, PLoS One 2013, to
has taken final action in the following
of the Patient Engagement Advisory represent immunoprecipitations for
case:
Committee would be held on October 11 phosphorylated GSK-3 (p-GSK-3) in
Azza El-Remessy, Ph.D., University of
and 12, 2017. On page 34681, in the cells with normal glucose or high
Georgia, College of Pharmacy: Based on
third column, the DATES section is glucose for day 1 and to also represent
the report of an investigation conducted
changed to reflect the time of these cells treated with VEGF or VEGF+VEGFI
by the University of Georgia, College of
meetings on the announced dates. (inhibitor); the Respondent also
Pharmacy (UGCP) and additional
duplicated GSK-3 controls by using the
On page 34682, in the first column, in analysis conducted by ORI in its
same bands to represent high glucose
the Procedure section, the third oversight review, ORI found that Dr.
treatment for day 1 and day 3
sentence is changed to reflect new times Azza El-Remessy, former Associate treatments, flipping them horizontally,
for oral presentations on October 11 and Professor, Department of Clinical and to also represent for VEGF and VEGFRI
12. Administrative Pharmacy, UGCP, treatments.
engaged in research misconduct in 5. Figure 3, FASEB J. 2007, to
On page 34682, in the second column, research supported by National Eye
a Webcast Information section is added represent phosphorylated VEGF2 (P-
Institute (NEI), National Institutes of VEGF2) protein expression in
before the last paragraph of the Health (NIH), grants R01 EY011766, R01
document. The amendments read as microvascular endothelial cells in:
EY022408, and R01 EY04618, National Lanes 1 and 8, lanes 2 and 5, and lanes
follows: Heart, Lung, and Blood Institute 6 and 7, where each lane represents
DATES: The meeting will be held on (NHLBI), NIH, grant R01 HL056259, and different experimental conditions.
October 11, 2017, from 12:30 p.m. to 6 National Cancer Institute (NCI), NIH, Dr. El-Remessy entered into a
p.m. and October 12, 2017, from 8 a.m. grant K01 CA89689. Voluntary Settlement Agreement
to 5 p.m. ORI found that false Western blot data (Agreement) to resolve this matter
were included in: without further expenditure of time or
Procedure: Oral presentations from • J Cell Sci. 118(Pt. 1):243–52, 2005 other resources. Dr. El-Remessy accepts
the public will be scheduled between (hereafter referred to as ‘‘J Cell Sci. ORI’s findings of research misconduct
approximately 2:30 p.m. to 3 p.m. on 2005’’). Retraction in: J Cell Sci. as set forth above but neither admits nor
October 11, 2017, and approximately 1 129(16):3203, 2016. denies ORI’s findings of research
p.m. to 2:30 p.m. on October 12, 2017. • FASEB J. 21(10):2528–39, 2007 misconduct. The settlement is not an
Webcast Information: This meeting (hereafter referred to as ‘‘FASEB J. admission of liability on the part of the
will also be made available to the public 2007’’). Retraction in: FASEB J. Respondent. Dr. El-Remessy voluntarily
via webcast. The links for the webcasts 31(1):421, 2017. agreed, beginning on September 12,
are below: October 11, 2017: ‘‘Patient • PLoS One 8(8):e71868, 2013 2017:
Engagement Advisory Committee (hereafter referred to as ‘‘PLoS One (1) To have her research supervised
Meeting, Day 1,’’ https:// 2013’’). for a period of three (3) years beginning
event.webcasts.com/ As a result of its investigation, UGCP with the effective date of the Agreement;
starthere.jsp?ei=1157277&tp_ recommended that PLoS One 2013 be Respondent agreed that prior to the
key=5580d0c7a5. October 12, 2017: corrected. As a result of the submission of an application for U.S.
‘‘Patient Engagement Advisory investigation, J Cell Sci. 2005 and Public Health Service (PHS) support for
FASEB J. 2007 have been retracted. a research project on which the
Committee Meeting, Day 2,’’ Morning
ORI found that Respondent Respondent’s participation is proposed
Session—https://event.webcasts.com/
intentionally, knowingly, or recklessly and prior to Respondent’s participation
starthere.jsp?ei=1157280&tp_
used the same Western blot bands to in any capacity on PHS-supported
key=dfcde848fe; and Afternoon
represent different experimental results. research, Respondent shall ensure that a
Session—https://event.webcasts.com/ Specifically, Respondent reused and plan for supervision of Respondent’s
starthere.jsp?ei=1157282&tp_ relabeled bands in: duties is submitted to ORI for approval;
key=6d832a247e. 1. Figure 3B, J Cell Sci. 2005, to the supervision plan must be designed
This notice is issued under the represent p38 bands from retinal to ensure the scientific integrity of
Federal Advisory Committee Act (5 cultured endothelial cells in high Respondent’s research contribution;
U.S.C. app. 2) and 21 CFR part 14, glucose in the absence of exogenous Respondent agreed that she shall not
VEGF and also cells in peroxynitrite in
sradovich on DSK3GMQ082PROD with NOTICES

relating to the advisory committees. participate in any PHS-supported
Dated: September 29, 2017.
the presence of exogenous VEGF. research until such a supervision plan is
2. Figure 4A, J Cell Sci. 2005, to submitted to and approved by ORI;
Anna K. Abram, represent nitrotyrosine Respondent agreed to maintain
Deputy Commissioner for Policy, Planning, immunoprecipitations from retinal responsibility for compliance with the
Legislation, and Analysis. endothelial cells cultured in normal agreed upon supervision plan;
[FR Doc. 2017–21317 Filed 10–3–17; 8:45 am] glucose in the presence or absence of (2) that for three (3) years beginning
BILLING CODE 4164–01–P FeTTP; the Respondent also duplicated with the effective date of the Agreement,

VerDate Sep<11>2014 20:18 Oct 03, 2017 Jkt 244001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\04OCN1.SGM 04OCN1

46252 Federal Register / Vol. 82, No. 191 / Wednesday, October 4, 2017 / Notices

any institution employing her shall Rockville, MD 20852 (Telephone Conference Place: National Institutes of Health,
submit, in conjunction with each Call). Neuroscience Center, 6001 Executive
application for PHS funds, or report, Contact Person: Rudy O. Pozzatti, Ph.D., Boulevard, Rockville, MD 20852.
Scientific Review Officer, Scientific Review Contact Person: Susan O. McGuire, Ph.D.,
manuscript, or abstract involving PHS-
Branch, National Human Genome Research Scientific Review Officer, Office of
supported research in which Institute, 5635 Fishers Lane, Suite 4076, MSC Extramural Policy and Review, National
Respondent is involved, a certification 9306, Rockville, MD 20852, (301) 402–0838, Institute on Drug Abuse, National Institutes
to ORI that the data provided by pozzattr@mail.nih.gov. of Health, DHHS, 6001 Executive Blvd.,
Respondent are based on actual (Catalogue of Federal Domestic Assistance Room 4245, Rockville, MD 20852, (301) 827–
experiments or are otherwise Program Nos. 93.172, Human Genome 5817, mcguireso@mail.nih.gov.
legitimately derived and that the data, Research, National Institutes of Health, HHS) Name of Committee: National Institute on
procedures, and methodology are Drug Abuse Special Emphasis Panel; NIH
Dated: September 28, 2017. Pathway to Independence Award (K99/R00).
accurately reported in the application,
Sylvia L. Neal, Date: October 25, 2017.
report, manuscript, or abstract;
(3) to exclude herself voluntarily from Program Analyst, Office of Federal Advisory Time: 1:00 p.m. to 5:00 p.m.
Committee Policy. Agenda: To review and evaluate grant
serving in any advisory capacity to PHS
[FR Doc. 2017–21263 Filed 10–3–17; 8:45 am] applications.
including, but not limited to, service on Place: National Institutes of Health,
any PHS advisory committee, board, BILLING CODE 4140–01–P
Neuroscience Center, 6001 Executive
and/or peer review committee, or as a Boulevard, Rockville, MD 20852.
consultant for a period of three (3) years, Contact Person: Susan O. McGuire, Ph.D.,
beginning with the effective date of the DEPARTMENT OF HEALTH AND Scientific Review Officer, Office of
Agreement; and HUMAN SERVICES Extramural Policy and Review, National
(4) that as a condition of the Institute on Drug Abuse, National Institutes
National Institutes of Health of Health, DHHS, 6001 Executive Blvd.,
Agreement, Respondent will request
that PLoS One 8(8):e71868, 2013 be Room 4245, Rockville, MD 20852, (301) 827–
National Institute on Drug Abuse; 5817, mcguireso@mail.nih.gov.
corrected or retracted. Notice of Closed Meetings Name of Committee: National Institute on
FOR FURTHER INFORMATION CONTACT:
Pursuant to section 10(d) of the Drug Abuse Special Emphasis Panel; (T32)
Director, Office of Research Integrity, Ruth L. Kirschstein National Research
1101 Wootton Parkway, Suite 750, Federal Advisory Committee Act, as
Service Award (NRSA) Institutional Research
Rockville, MD 20852, (240) 453–8200. amended, notice is hereby given of the Training Grants.
following meetings. Date: October 26–27, 2017.
Kathryn M. Partin, The meetings will be closed to the Time: 8:00 a.m. to 5:00 p.m.
Director, Office of Research Integrity. public in accordance with the Agenda: To review and evaluate grant
[FR Doc. 2017–21367 Filed 10–3–17; 8:45 am] provisions set forth in sections applications.
BILLING CODE 4150–31–P 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Place: National Institutes of Health,
as amended. The grant applications and Neuroscience Center, 6001 Executive
the discussions could disclose Boulevard, Rockville, MD 20852.
DEPARTMENT OF HEALTH AND confidential trade secrets or commercial Contact Person: Susan O. McGuire, Ph.D.
Scientific Review Officer, Office of
HUMAN SERVICES property such as patentable material,
Extramural Policy and Review, National
and personal information concerning Institute on Drug Abuse, National Institutes
National Institutes of Health individuals associated with the grant of Health, DHHS, 6001 Executive Blvd.,
applications, the disclosure of which Room 4245, Rockville, MD 20852, (301) 827–
National Human Genome Research would constitute a clearly unwarranted 5817, mcguireso@mail.nih.gov.
Institute; Notice of Closed Meeting invasion of personal privacy. Name of Committee: National Institute on
Pursuant to section 10(d) of the Name of Committee: National Institute on Drug Abuse Special Emphasis Panel;
Federal Advisory Committee Act, as Drug Abuse Special Emphasis Panel; Multi- Exploring Novel RNA Modifications in HIV/
amended, notice is hereby given of the site Clinical Trials. AIDS and Substance Use Disorders (R01,
following meeting. Date: October 19, 2017. R21).
Time: 1:00 p.m. to 5:00 p.m. Date: November 1, 2017.
The meeting will be closed to the
Agenda: To review and evaluate grant Time: 9:00 a.m. to 5:00 p.m.
public in accordance with the Agenda: To review and evaluate grant
applications.
provisions set forth in sections Place: National Institutes of Health, applications.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Neuroscience Center, 6001 Executive Place: National Institutes of Health,
as amended. The grant applications and Boulevard, Rockville, MD 20852, (Telephone Neuroscience Center, 6001 Executive
the discussions could disclose Conference Call). Boulevard, Rockville, MD 20852,
confidential trade secrets or commercial Contact Person: Shang-Yi Anne Tsai, Contact Person: Susan O. McGuire, Ph.D.,
property such as patentable material, Ph.D., Scientific Review Officer, Office of Scientific Review Officer, Office of
and personal information concerning Extramural Policy and Review, Division of Extramural Policy and Review, National
Extramural Research, National Institute on Institute on Drug Abuse, National Institutes
individuals associated with the grant
Drug Abuse, NIH, DHHS, 6001 Executive of Health, DHHS, 6001 Executive Blvd.,
applications, the disclosure of which Boulevard, Room 4228, MSC 9550, Bethesda, Room 4245, Rockville, MD 20852, (301) 827–
would constitute a clearly unwarranted MD 20892, 301–827–5842, shangyi.tsai@ 5817, mcguireso@mail.nih.gov.
invasion of personal privacy. nih.gov. Name of Committee: National Institute on
Name of Committee: National Human Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Cutting-
sradovich on DSK3GMQ082PROD with NOTICES

Genome Research Institute Special Emphasis Drug Abuse Special Emphasis Panel; NIDA Edge Basic Research Awards (CEBRA) (R21).
Panel, SEP U24 Research Resource. Mentored Clinical Scientists Development Date: November 29, 2017.
Date: November 30, 2017. Program Award in Drug Abuse and Time: 9:00 a.m. to 5:00 p.m.
Time: 11:00 a.m. to 2:00 p.m. Addiction (K12). Agenda: To review and evaluate grant
Agenda: To review and evaluate grant Date: October 25, 2017. applications.
applications. Time: 9:00 a.m. to 12:00 p.m. Place: Bethesda North Marriott Hotel &
Place: National Human Genome Research Agenda: To review and evaluate grant Conference Center, 5701 Marinelli Road,
Institute, 5635 Fishers Lane, Suite 3146, applications. Bethesda, MD 20852.

VerDate Sep<11>2014 20:18 Oct 03, 2017 Jkt 244001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\04OCN1.SGM 04OCN1

Document Created: 2018-10-25 09:53:20
Document Modified: 2018-10-25 09:53:20

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.
FR Citation		82 FR 46251

82 FR 46251 - Findings of Research Misconduct

DEPARTMENT OF HEALTH AND HUMAN SERVICESOffice of the Secretary

Federal Register Volume 82, Issue 191 (October 4, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary